Printer Friendly

VENTURE CAPITAL COMPANY CREATES BUSINESS OPPORTUNITIES FOR THOUSANDS OF PEOPLE

 VENTURE CAPITAL COMPANY CREATES BUSINESS OPPORTUNITIES
 FOR THOUSANDS OF PEOPLE
 NEWPORT BEACH, Calif., May 6 /PRNewswire/ -- International Daleco Corp. (NASDAQ: ILDO) has formed a wholly owned subsidiary, NEOCARE Laboratories Inc., to help solve the unemployment crisis by creating new career and part-time job opportunities. International Daleco has invested more than $1.5 million and has spent almost two years organizing and planning the launch of NEOCARE. NEOCARE's initial objective is to provide flexible, independent employment opportunities to more than 100,000 people.
 NEOCARE is pleased to report that after only one week in business, the company has already exceeded its first month objective and has provided 148 new job opportunities to businesspeople in varying stages of their careers, ranging from those at the height of their earning ability to retirees seeking supplemental income and mothers re-entering the workforce. The NEOCARE opportunity is available to all people, regardless of their race, religion, ethnic or educational backgrounds.
 In addition to generating job opportunities, NEOCARE has developed three lines of proprietary consumer products: a nutritional line, an environmental line and a skin care line. Each of the NEOCARE products has been designed to include elements of the most recent innovations in biotechnology, immunology and enzymology.
 Since its inception in 1979, NEOCARE's parent company, International Daleco Corp., has been concerned with stimulating the U.S. economy. Daleco has provided approximately $100 million of venture capital to more than one dozen companies with technologically innovative products. During this time, Daleco has worked with some of the country's most prestigious research institutions and universities, including The Mellon Institute, Georgia Institute of Technology and Stanford Research Institute. The range of products and technologies financed by Daleco has encompassed such fields as enzymology, biotechnology, pharmaceuticals, aviation, energy, electronics, chemistry and consumer goods. Daleco holds, and continues to hold, various royalty and equity (stock and warrant) positions in these companies.
 For 13 years, through its financing of new technologies and products, Daleco has indirectly created hundreds of jobs. However, the creation of its new wholly owned subsidiary, NEOCARE, and its proprietary line of consumer products offered through an independent distributor network, allows Daleco to focus more directly on its goal of providing job opportunities for thousands of Americans and to contribute toward loosening the unemployment stranglehold currently suffocating this country.
 -0- 5/6/92
 /CONTACT: Parker Dale, president of International Daleco, 800-432-5326/
 (ILDO) CO: International Daleco Corp.; NEOCARE ST: California IN: SU:


JL-AL -- LAFNS1 -- 6872 05/06/92 07:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1992
Words:412
Previous Article:FOR THOSE DIAGNOSED WITH AN ASTIGMATISM, THERE'S GOOD NEWS FROM BAUSCH & LOMB
Next Article:THE GLIDDEN COMPANY RECEIVES 1992 OHIO FRIEND OF EDUCATION AWARD
Topics:


Related Articles
Capitalist tool.
Sierra Ventures to Invest $11 Million in NovaMed Eyecare Management
Brentwood Venture Capital Closes $300 Million Fund - Its Largest Ever.
Draper Atlantic Partners with Trancentrix, Inc.
News Corporation's Fox Interactive Media and Foundation Capital Invest $13.5M in Job Search Engine Simply Hired.
Stardoll.com Closes US$6m Series B Funding Led by Sequoia Capital and Adds Prominent Entertainment Industry Lawyer to Board.
Stardoll.com Closes $6m Series B Funding Led by Sequoia Capital and Adds Prominent Entertainment Industry Lawyer to Board.
LiveOps Fuels Expansion With $28 Million in Series C Financing Led by Benchmark Capital.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters